4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ocumension Therapeutics (1477) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 552 employees. Its market capitalization is roughly CNY 4 billion. In the fiscal year ended 2025-12-31, 1477 reported CNY 804M in revenue and (CNY 159M) in net income.
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 804M | CNY 417M | CNY 246M | CNY 159M | — |
| Gross Profit | CNY 361M | CNY 225M | CNY 144M | CNY 103M | — |
| Operating Income (EBIT) | (CNY 156M) | (CNY 304M) | (CNY 401M) | (CNY 448M) | — |
| Net Income | (CNY 159M) | (CNY 268M) | (CNY 380M) | (CNY 403M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 4.1B | CNY 4.0B | CNY 3.3B | CNY 3.0B | — |
| Total Liabilities | CNY 410M | CNY 200M | CNY 351M | CNY 295M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1477 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms